Sign In
Buy PFE
$26.04
+0.350 (+1.36%)
At Close: Jun 05, 2026
U.S. known COVID cases hold at lowest level since May, but infections are rising again in New York
06:50pm, Tuesday, 13'th Sep 2022 MarketWatch
U.S. known cases of COVID are continuing to ease and now stand at their lowest level since early May, although the numbers need to be viewed gently, given the number of people testing at home, where t
Pfizer (PFE), BioNTech Omicron BA.4, BA.5 Boosters Get CHMP Nod
04:05pm, Tuesday, 13'th Sep 2022 Zacks Investment Research
Pfizer (PFE) and BioNTech (BNTX) get a positive recommendation from CHMP for Omicron BA.4 and BA.5-adapted bivalent vaccines.
Novavax (NVAX) Gets EU Nod for COVID-19 Booster Jab in Adults
03:20pm, Tuesday, 13'th Sep 2022 Zacks Investment Research
Novavax (NVAX) gets authorization from the European Union to use its COVID-19 vaccine as a booster dose in adults.
Ideaya (IDYA) Up on Interim Data from Mid-Stage Eye Cancer Study
03:18pm, Tuesday, 13'th Sep 2022 Zacks Investment Research
Ideaya Biosciences (IDYA) reports positive interim results from its mid-stage study, evaluating darovasertib in combination with Pfizer's Xalkori (crizotinib) in metastatic uveal melanoma. Stock up.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
10:20am, Tuesday, 13'th Sep 2022 Zacks Investment Research
Sector ETF report for IHE
Pfizer (PFE) Alopecia Drug Filings Get Accepted by FDA, EMA
04:22pm, Monday, 12'th Sep 2022 Zacks Investment Research
FDA accepts Pfizer's (PFE) NDA for ritlecitinib for treating severe alopecia areata. The EMA also accepts the MAA for a similar patient population.
Want Passive Income? Buy These 2 Beaten-Down Dividend Stocks
11:35am, Saturday, 10'th Sep 2022 The Motley Fool
If you want to secure a decent yield, it can pay to buy shares of strong companies dealing with short-term problems.
Pharma Stock Roundup: FDA Nod to AZN's Imfinzi for New Cancer & Other Updates
05:20pm, Friday, 09'th Sep 2022 Zacks Investment Research
FDA approves AstraZeneca's (AZN) Imfinzi combination for advanced metastatic biliary tract cancer and grants Breakthrough Therapy Designation to Pfizer's (PFE) Group B Streptococcus (GBS) vaccine.
This Troubling News Could Put a Dent in Pfizer's Sales
02:00pm, Friday, 09'th Sep 2022 The Motley Fool
A new study out of Israel suggests that COVID-19 drug Paxlovid may not be effective in treating adults under 65.
Here's Why These Top 3 COVID-19 Vaccine Stocks Broke Down in August
05:00pm, Thursday, 08'th Sep 2022 The Motley Fool
Pfizer, Moderna, and Novavax all had a rough month in August.
Pfizer (PFE) Streptococcus Jab Gets FDA's Breakthrough Tag
01:37pm, Thursday, 08'th Sep 2022 Zacks Investment Research
Pfizer (PFE) gets Breakthrough Therapy Designation for GBS vaccine candidate, GBS6, based on an interim analysis of a phase II study.
Zacks Market Edge Highlights: General Electric, IBM, Pfizer, Bank of America and McDonald's
11:20am, Thursday, 08'th Sep 2022 Zacks Investment Research
Zacks Market Edge Highlights: General Electric, IBM, Pfizer, Bank of America and McDonald's
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
10:20am, Thursday, 08'th Sep 2022 Zacks Investment Research
Sector ETF report for IYH
5 Best And Worst Performing Mega-Cap Stocks In August 2022
06:48am, Thursday, 08'th Sep 2022 Investing.com
Pfizer (PFE) Gains But Lags Market: What You Should Know
09:45pm, Wednesday, 07'th Sep 2022 Zacks Investment Research
Pfizer (PFE) closed the most recent trading day at $46.13, moving +0.81% from the previous trading session.
